Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Acumen Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEWTON, MASS., JULY 15, 2026 (GLOBE NEWSWIRE) -- ACUMEN PHARMACEUTICALS, INC.(NASDAQ: ABOS) (ACUMEN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS THAT TARGET SOLUBLE AMYLOID BETA OLIGOMERS (AOS) FOR THE TREATMENT OF ALZHEIMER'S DISEASE (AD),TODAY ANNOUNCED NEW FINDINGS PRESENTED AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2026 IN LONDON. FOLLOWING COLLABORATION WITH JCR PHARMACEUTICALS CO., LTD. (JCR) ON EBD CANDIDATE DEVELOPMENT, STUDIES DEMONSTRATED IMPROVED BRAIN PENETRATION OF ANTI-AO ANTIBODIES THROUGH TRANSFERRIN RECEPTOR-MEDIATED DELIVERY ACROSS BOTH MOUSE AND NON-HUMAN PRIMATE MODELS. ADDITIONALLY, RESEARCH FROM EARLY SYMPTOMATIC AD PATIENTS HIGHLIGHTED THE LIVED EXPERIENCE AMONG ALTITUDE-AD TRIAL PARTICIPANTS AND THEIR STUDY PARTNERS.

ACUMEN PHARMACEUTICALS HIGHLIGHTS ENHANCED BRAIN DELIVERY (EBD) PROGRAM DATA AND EARLY ALZHEIMER'S DISEASE INSIGHTS AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2026

NEWTON, MASS., JULY 07, 2026 (GLOBE NEWSWIRE) -- ACUMEN PHARMACEUTICALS, INC.(NASDAQ: ABOS) (ACUMEN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS THAT TARGET SOLUBLE AMYLOID BETA OLIGOMERS (AOS) FOR THE TREATMENT OF ALZHEIMER'S DISEASE (AD),WILL PRESENT THREE KEY STUDIES AT THE UPCOMING ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2026 IN LONDON. SHARED IN ONE ORAL AND TWO POSTER PRESENTATIONS, THE DATA HIGHLIGHT ACUMEN'S PROGRESS WITH JCR PHARMACEUTICALS (JCR), IN DEVELOPING NEXT GENERATION THERAPEUTICS THROUGH ENHANCED BRAIN DELIVERY (EBD) TECHNOLOGY AND EXPANDING THE FIELD'S UNDERSTANDING OF EARLY SYMPTOMATIC AD THROUGH THE PATIENT LENS. THE CONFERENCE WILL BE HELD JULY 12-15, 2026, BOTH IN-PERSON AND ONLINE.

ACUMEN PHARMACEUTICALS TO PRESENT DATA ON ENHANCED BRAIN DELIVERY (EBD) TECHNOLOGY AND EARLY ALZHEIMER'S DISEASE INSIGHTS AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2026

HYOGO, JAPAN--(BUSINESS WIRE)--JCR PHARMACEUTICALS CO., LTD. (TSE 4552; JCR), A GLOBAL SPECIALTY BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING THERAPIES FOR RARE AND GENETIC DISEASES, TODAY ANNOUNCED THAT ACUMEN PHARMACEUTICALS, INC. (NASDAQ: ABOS) EXERCISED ITS EXCLUSIVE OPTION TO DEVELOP, MANUFACTURE, AND COMMERCIALIZE, ON A GLOBAL BASIS, UP TO TWO CANDIDATES FOR DEVELOPMENT IN THE TREATMENT OF ALZHEIMER'S DISEASE (AD), ENABLED BY JCR'S PROPRIETARY BLOOD-BRAIN BARRIER (BBB)-PENETRATING TECHNOLOGY PLATFORM, J-BRAIN CARGO

JCR PHARMACEUTICALS ANNOUNCES THAT ACUMEN PHARMACEUTICALS HAS EXERCISED ITS EXCLUSIVE OPTION TO DEVELOP THERAPEUTIC CANDIDATES FOR ALZHEIMER'S DISEASE, ENABLED BY J-BRAIN CARGO TECHNOLOGY PLATFORM

ACU301 AND ACU401 WERE NOMINATED IN THE EBD PROGRAM AS PART OF THE EXERCISE OF ACUMEN'S OPTION UNDER ITS LICENSE AGREEMENT WITH JCR PHARMACEUTICALS EBD TECHNOLOGY REPRESENTS THE ONLY ANTI-AMYLOID OLIGOMER PROGRAM COMBINING A VALIDATED BLOOD-BRAIN BARRIER-PENETRATING TECHNOLOGY WITH A THERAPEUTIC ANTIBODY TESTED IN THE CLINIC ACUMEN'S EBD CANDIDATES ARE DESIGNED TO ACHIEVE HIGHER BRAIN PENETRATION WITH POTENTIAL FOR IMPROVED SAFETY COMPARED TO NATIVE ANTIBODIES AND DELIVERED IN A STABLE, LOW VOLUME SUBCUTANEOUS ADMINISTRATION FORMAT INVESTIGATIONAL NEW DRUG (IND)-ENABLING ACTIVITIES ARE ONGOING TO SUPPORT IND SUBMISSION IN MID-2027 NEWTON, MASS., JUNE 16, 2026 (GLOBE NEWSWIRE) -- ACUMEN PHARMACEUTICALS, INC. (NASDAQ: ABOS) (ACUMEN OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS THAT TARGET SOLUBLE AMYLOID BETA OLIGOMERS (AOS) FOR THE TREATMENT OF ALZHEIMER'S DISEASE (AD), TODAY ANNOUNCED THE NOMINATION OF TWO DEVELOPMENT CANDIDATES IN ITS ENHANCED BRAIN DELIVERY (EBD) PROGRAM AS TREATMENTS FOR AD.

ACUMEN PHARMACEUTICALS ANNOUNCES NOMINATION OF TWO ENHANCED BRAIN DELIVERY (EBD) DEVELOPMENT CANDIDATES FOR THE TREATMENT OF ALZHEIMER'S DISEASE

NEWTON, MASS., MAY 12, 2026 (GLOBE NEWSWIRE) -- ACUMEN PHARMACEUTICALS, INC. (NASDAQ: ABOS) (ACUMEN OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS THAT TARGET TOXIC SOLUBLE AMYLOID BETA OLIGOMERS (AOS) FOR THE TREATMENT OF ALZHEIMER'S DISEASE (AD), TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2026 AND PROVIDED A BUSINESS UPDATE.

ACUMEN PHARMACEUTICALS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

NEWTON, MASS., MAY 07, 2026 (GLOBE NEWSWIRE) -- ACUMEN PHARMACEUTICALS, INC. (NASDAQ: ABOS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS THAT TARGET TOXIC SOLUBLE AMYLOID BETA OLIGOMERS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, ANNOUNCED TODAY THAT MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE BANK OF AMERICA SECURITIES 2026 HEALTH CARE CONFERENCE ON THURSDAY, MAY 14, 2026, AT 8:55 A.M.

ACUMEN PHARMACEUTICALS TO PARTICIPATE IN THE BANK OF AMERICA SECURITIES 2026 HEALTH CARE CONFERENCE

NEWTON, MASS., MAY 05, 2026 (GLOBE NEWSWIRE) -- ACUMEN PHARMACEUTICALS, INC. (NASDAQ: ABOS) (ACUMEN OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS THAT TARGET TOXIC SOLUBLE AMYLOID BETA OLIGOMERS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, TODAY ANNOUNCED THAT THE COMPANY WILL REPORT FIRST QUARTER FINANCIAL RESULTS ON TUESDAY, MAY 12, 2026.

ACUMEN PHARMACEUTICALS TO REPORT FIRST QUARTER FINANCIAL RESULTS ON MAY 12, 2026

NEWTON, MASS., MARCH 26, 2026 (GLOBE NEWSWIRE) -- ACUMEN PHARMACEUTICALS, INC. (NASDAQ: ABOS) (ACUMEN OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS THAT TARGET TOXIC SOLUBLE AMYLOID BETA OLIGOMERS (AOS) FOR THE TREATMENT OF ALZHEIMER'S DISEASE (AD), TODAY REPORTED FINANCIAL RESULTS FOR THE FULL YEAR ENDED DECEMBER 31, 2025 AND PROVIDED A BUSINESS UPDATE.

ACUMEN PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025 AND BUSINESS HIGHLIGHTS

NEWTON, MASS., MARCH 19, 2026 (GLOBE NEWSWIRE) -- ACUMEN PHARMACEUTICALS, INC. (NASDAQ: ABOS) (ACUMEN OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS THAT TARGET TOXIC SOLUBLE AMYLOID BETA OLIGOMERS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, TODAY ANNOUNCED THAT THE COMPANY WILL REPORT FOURTH QUARTER AND YEAR-END 2025 FINANCIAL RESULTS ON THURSDAY, MARCH 26, 2026. THE COMPANY WILL HOST A CONFERENCE CALL AND LIVE AUDIO WEBCAST AT 8:00 A.M. ET TO PROVIDE A BUSINESS AND FINANCIAL UPDATE.

ACUMEN PHARMACEUTICALS TO REPORT FOURTH QUARTER AND YEAR-END 2025 FINANCIAL RESULTS ON MARCH 26, 2026

NEWTON, MASS., MARCH 16, 2026 (GLOBE NEWSWIRE) -- ACUMEN PHARMACEUTICALS, INC. (NASDAQ: ABOS) (ACUMEN OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS THAT TARGET TOXIC SOLUBLE AMYLOID B OLIGOMERS (AOS) FOR THE TREATMENT OF ALZHEIMER'S DISEASE (AD), TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH CERTAIN INSTITUTIONAL AND ACCREDITED INVESTORS FOR A PRIVATE PLACEMENT OF APPROXIMATELY $35.75 MILLION OF SHARES OF ITS COMMON STOCK AT A PRICE OF $3.30 PER SHARE. ACUMEN EXPECTS TO RECEIVE GROSS PROCEEDS FROM THE OFFERING OF APPROXIMATELY $35.75 MILLION, BEFORE DEDUCTING OFFERING EXPENSES.

ACUMEN PHARMACEUTICALS ANNOUNCES $35.75 MILLION PRIVATE PLACEMENT TO ADVANCE POTENTIAL BEST-IN-CLASS MOLECULES FROM AMYLOID BETA OLIGOMER-SELECTIVE ENHANCED BRAIN DELIVERY PORTFOLIO

Acumen Pharmaceuticals, Inc.

ABOS

Price

Financial Reports

No items found.

Press Releases

Acumen Pharmaceuticals, Inc.

ABOS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ABOS